- Home
- PTCT vs CGON Comparison
PTCT vs CGON Comparison
Compare PTCT & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTCT
- CGON
- Stock Information
- Founded
- PTCT 1998
- CGON 2010
- Country
- PTCT United States
- CGON United States
- Employees
- PTCT N/A
- CGON N/A
- Industry
- PTCT Biotechnology: Pharmaceutical Preparations
- CGON
- Sector
- PTCT Health Care
- CGON
- Exchange
- PTCT Nasdaq
- CGON NYSE
- Market Cap
- PTCT 2.5B
- CGON 2.3B
- IPO Year
- PTCT 2013
- CGON 2024
- Fundamental
- Price
- PTCT $34.70
- CGON $36.35
- Analyst Decision
- PTCT Hold
- CGON Strong Buy
- Analyst Count
- PTCT 16
- CGON 6
- Target Price
- PTCT $36.80
- CGON $64.17
- AVG Volume (30 Days)
- PTCT 484.5K
- CGON 567.1K
- Earning Date
- PTCT 10-24-2024
- CGON 11-02-2024
- Dividend Yield
- PTCT N/A
- CGON N/A
- EPS Growth
- PTCT N/A
- CGON N/A
- EPS
- PTCT N/A
- CGON N/A
- Revenue
- PTCT $900,454,000.00
- CGON $539,000.00
- Revenue This Year
- PTCT N/A
- CGON $478.43
- Revenue Next Year
- PTCT N/A
- CGON $415.25
- P/E Ratio
- PTCT N/A
- CGON N/A
- Revenue Growth
- PTCT 9.98
- CGON N/A
- 52 Week Low
- PTCT $17.53
- CGON $25.77
- 52 Week High
- PTCT $40.69
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- PTCT 52.51
- CGON N/A
- Support Level
- PTCT $30.98
- CGON N/A
- Resistance Level
- PTCT $32.30
- CGON N/A
- Average True Range (ATR)
- PTCT 1.43
- CGON 0.00
- MACD
- PTCT -0.13
- CGON 0.00
- Stochastic Oscillator
- PTCT 52.33
- CGON 0.00
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.